{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:53:35Z","timestamp":1788382415795,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd008794","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000}}],"reference-count":290,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008794.pub2","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T13:45:04Z","timestamp":1296827104000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":248,"title":["Adverse effects of biologics: a network meta-analysis and Cochrane overview"],"prefix":"10.1002","volume":"2016","author":[{"given":"Jasvinder A","family":"Singh","sequence":"first","affiliation":[{"name":"Birmingham VA Medical Center; Department of Medicine; Faculty Office Tower 805B 510 20th Street South Birmingham AL USA 35294"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; Room H1281 40 Ruskin Street Ottawa ON Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital, Bispebjerg og Frederiksberg; Musculoskeletal Statistics Unit, The Parker Institute; Nordre Fasanvej 57 Copenhagen Denmark DK-2000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tanjong Ghogomu","sequence":"additional","affiliation":[{"name":"University of Ottawa; Bruy\u00e8re Research Institute; 43 Bruy\u00e8re St Annex E, room 302 Ottawa ON Canada K1N 5C8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara J","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus; Centre for Practice-Changing Research (CPCR); 501 Smyth Road, Box 711 Ottawa ON Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Scientific Direction; via Celoria, 11 Milano Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian K","family":"Francis","sequence":"additional","affiliation":[{"name":"University of West Indies; Epidemiology Research Unit; Mona Kingston 7 Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane C","family":"Lopes","sequence":"additional","affiliation":[{"name":"University of Sorocaba, S\u00e3o Paulo; Sciences of Pharmaceutical Program; Rodovia Raposo Tavares, s\/n Sorocaba S\u00e3o Paulo Brazil CEP 18023-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H","family":"Guyatt","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Clinical Epidemiology and Biostatistics; 1200 Main Street West Hamilton ON Canada L8N 3Z5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Carl Gustav Carus, Technischen Universit\u00e4t (TU) Dresden; Center for Evidence-Based Healthcare; Fetscherstr. 74 Dresden Germany 01307"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"La Mantia","sequence":"additional","affiliation":[{"name":"I.R.C.C.S. Santa Maria Nascente - Fondazione Don Gnocchi; Unit of Neurorehabilitation - Multiple Sclerosis Center; Via Capecelatro, 66 Milano Italy 20148"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Weberschock","sequence":"additional","affiliation":[{"name":"Goethe University; Evidence-Based Medicine Frankfurt, Institute of General Practice; Theodor Stern Kai 7 Frankfurt Germany 60590"},{"name":"J.W. Goethe-University Hospital; Department of Dermatology, Venereology, and Allergology; Theodor-Stern-Kai 7 Frankfurt Germany 60590"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana F","family":"Roos","sequence":"additional","affiliation":[{"name":"Dubai Pharmacy College; Dept of Clinical Pharmacy & Pharmacy Practice; Po Box 19099 AlMuhaisanah 1, Al mizhar Dubai United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Siebert","sequence":"additional","affiliation":[{"name":"University Hospital Cologne; Cochrane Haematological Malignancies Group; Kerpener Strasse 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hershan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology at Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cameron","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; Room H1281 40 Ruskin Street Ottawa ON Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael PT","family":"Lunn","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; Department of Neurology and MRC Centre for Neuromuscular Diseases; Queen Square London UK WC1N 3BG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5"},{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa ON Canada K1Y 4E9"},{"name":"Faculty of Medicine, University of Ottawa; Department of Epidemiology and Community Medicine; Ottawa ON Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"10.1002\/14651858.CD008794.pub2-BIB0001|cit1","first-page":"37","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis","volume":"33","author":"Abe","year":"2006","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).[Erratum appears in Arthritis Rheum. 2005 Sep;52(9):2951]","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0004|cit4","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/cbr.2006.360","article-title":"Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial","volume":"22","author":"Aviles","year":"2007","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02685907","article-title":"Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma","volume":"24","author":"Aviles","year":"2007","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"22","key":"10.1002\/14651858.CD008794.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/03009740600844530","article-title":"A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis","volume":"35","author":"Bliddal","year":"2006","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.[Erratum appears in Rheumatology (Oxford). 2005 Apr;44(4):569]","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology"},{"issue":"9313","key":"10.1002\/14651858.CD008794.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ard.2004.025130","article-title":"Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"64","author":"Braun","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/ard.2007.075879","article-title":"Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response","volume":"67","author":"Braun","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","article-title":"The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/205873920601900123","article-title":"Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study)","volume":"19","author":"Cassano","year":"2006","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"9271","key":"10.1002\/14651858.CD008794.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0929-6646(09)60071-1","article-title":"Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis","volume":"108","author":"Chen","year":"2009","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"25","key":"10.1002\/14651858.CD008794.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.mao.0000185082.28598.87","article-title":"Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study","volume":"26","author":"Cohen","year":"2005","journal-title":"Otology & Neurotology"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0031|cit31","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/ard.2007.087106","article-title":"Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study","volume":"68","author":"Combe","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2008.306","article-title":"A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma","volume":"43","author":"Copelan","year":"2009","journal-title":"Bone Marrow Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/art.20241","article-title":"Results from an open-label extension study of etanercept in ankylosing spondylitis","volume":"51","author":"Davis","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0039|cit39","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"Broeder","year":"2002","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3899\/jrheum.081033","article-title":"Etanercept in the longterm treatment of patients with ankylosing spondylitis","volume":"36","author":"Dijkmans","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1002\/art.23055","article-title":"Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone","volume":"56","author":"Durez","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"25","key":"10.1002\/14651858.CD008794.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.[Erratum appears in Ann Rheum Dis. 2009 Feb;68(2):296]","volume":"67","author":"Emery","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428190802688509","article-title":"Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study","volume":"50","author":"Eve","year":"2009","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"43","key":"10.1002\/14651858.CD008794.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1055\/s-2002-35017","article-title":"[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]","volume":"127","author":"Forstpointner","year":"2002","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"10","key":"10.1002\/14651858.CD008794.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0056|cit56","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study","volume":"66","author":"Furst","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"76","key":"10.1002\/14651858.CD008794.pub2-BIB0058|cit58","first-page":"1074","article-title":"Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients","volume":"54","author":"Gavalas","year":"2007","journal-title":"Hepato-Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.[Erratum appears in N Engl J Med. 2005 Nov 24;353(21):2311]","volume":"353","author":"Genovese","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0061|cit61","first-page":"1232","article-title":"Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0062|cit62","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.[Erratum appears in J Rheumatol. 2007 Jun;34(6):1439]","volume":"34","author":"Genovese","year":"2007","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD008794.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.[Erratum appears in J Dermatolog Treat. 2006;17(3):192]","volume":"17","author":"Gordon","year":"2006","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"18","key":"10.1002\/14651858.CD008794.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2003.307","article-title":"Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis","volume":"48","author":"Gottlieb","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"9317","key":"10.1002\/14651858.CD008794.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0080|cit80","first-page":"164","article-title":"Acute toxicity of mitoxantrone, chlorambucil and prednisolone (MCP) versus MCP plus rituximab in low-grade non-Hodgkin's lymphoma - Interim results of a phase III trial","volume":"23","author":"Herold","year":"2000","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0086|cit86","first-page":"659","article-title":"Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study","volume":"33","author":"Johnsen","year":"2006","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study","volume":"69","author":"Jones","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0088|cit88","first-page":"841","article-title":"Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.[Erratum appears in Arthritis Rheum. 2009 May;60(5):1249]","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1479-8077.2007.00248.x","article-title":"A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate","volume":"10","author":"Kim","year":"2007","journal-title":"APLAR Journal of Rheumatology"},{"issue":"9410","key":"10.1002\/14651858.CD008794.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/ard.2005.038349","article-title":"A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs","volume":"65","author":"Klareskog","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/art.11142","article-title":"Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations","volume":"48","author":"Kremer","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.[Erratum appears in Arthritis Rheum. 2005 Oct;52(10):3321]","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.[Summary for patients in Ann Intern Med. 2006 Jun 20;144(12):I18; PMID: 16785473]","volume":"144","author":"Kremer","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.jaad.2005.10.054","article-title":"Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial","volume":"54","author":"Krueger","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0104|cit104","first-page":"618","article-title":"A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study","volume":"103","author":"Lan","year":"2004","journal-title":"Journal of the Formosan Medical Association"},{"issue":"21","key":"10.1002\/14651858.CD008794.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0106|cit106","first-page":"1421","article-title":"[Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China - a multi-center randomized trial]","volume":"24","author":"Lin","year":"2005","journal-title":"Aizheng: Chinese Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"9194","key":"10.1002\/14651858.CD008794.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in Arthritis Rheum. 2008 Mar;58(3):887]","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9227","key":"10.1002\/14651858.CD008794.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD008794.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0117|cit117","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"Jourunal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"Journal of the Americn Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/s10165-008-0045-0","article-title":"Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study","volume":"18","author":"Miyasaka","year":"2008","journal-title":"Modern Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.2005.04.2838","article-title":"Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients","volume":"24","author":"Monk","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD008794.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/17469872.3.6.657","article-title":"Efficacy and safety of continuous versus paused etanercept teatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL study","volume":"3","author":"Ortonne","year":"2008","journal-title":"Expert Review of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/ard.2008.090860","article-title":"Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy","volume":"68","author":"Pavelka","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"22","key":"10.1002\/14651858.CD008794.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet: Oncology"},{"issue":"18","key":"10.1002\/14651858.CD008794.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03009740410005467","article-title":"Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate","volume":"33","author":"Rau","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"9494","key":"10.1002\/14651858.CD008794.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0136|cit136","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.rmed.2005.02.031","article-title":"Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation","volume":"99","author":"Rouhani","year":"2005","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1002\/14651858.CD008794.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.[Summary for patients in Ann Intern Med. 2007 May 1;146(9):I20; PMID: 17470827]","volume":"146","author":"Salvarani","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.[Summary for patients in Ann Intern Med. 2007 Jun 19;146(12):I20; PMID: 17470825]","volume":"146","author":"Sandborn","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflammatory Bowel Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard.2005.037499","article-title":"Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis","volume":"64","author":"Sany","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/art.20277","article-title":"The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions","volume":"50","author":"Schiff","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.[Erratum appears in Gastroenterology. 2005 Nov;129(5):1808 Note: Dosage error in article text]","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease.[Erratum appears in N Engl J Med. 2007 Sep 27;357(13):1357]","volume":"357","author":"Schreiber","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9617","key":"10.1002\/14651858.CD008794.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9685","key":"10.1002\/14651858.CD008794.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.[Erratum appears in Lancet. 2009 Oct 24;374(9699):1422]","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study","volume":"37","author":"Spahr","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"Clair","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.tp.0000276990.78659.77","article-title":"The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy","volume":"84","author":"Torre-Amione","year":"2007","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/TP.0b013e3181a235fd","article-title":"A randomized, double blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation","volume":"87","author":"Tyden","year":"2009","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD008794.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0961203309102557","article-title":"Efficacy and safety of infliximab in active SLE: a pilot study","volume":"18","author":"Uppal","year":"2009","journal-title":"Lupus"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0161|cit161","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"Kerkhof","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","article-title":"Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study","volume":"62","author":"Putte","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"Putte","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Bosch","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/art.24513","article-title":"Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial","volume":"61","author":"Bijl","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Heijde","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Heijde","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"Heijde","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/art.23141","article-title":"Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis","volume":"56","author":"Heijde","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard.2007.076166","article-title":"The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy","volume":"67","author":"Heijde","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"Heijde","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","article-title":"First study of infliximab treatment in patients with chronic obstructive pulmonary disease","volume":"172","author":"Vaart","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9688","key":"10.1002\/14651858.CD008794.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"Vollenhoven","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial Research Group","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study","volume":"65","author":"Weinblatt","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"228\u201334","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.23493","article-title":"Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kem033","article-title":"A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases","volume":"46","author":"Weisman","year":"2007","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.[Erratum appears in Arthritis Rheum. 2007 May;56(5):1675 Note: Dosage error in article text]","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3899\/jrheum.080813","article-title":"Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study","volume":"36","author":"Westhovens","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD008794.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/ard.2008.101121","article-title":"Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors","volume":"68","author":"Westhovens","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0187|cit187","first-page":"18","article-title":"A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"Journal of Supportive Oncology"},{"issue":"10","key":"10.1002\/14651858.CD008794.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"20 Pt 1","key":"10.1002\/14651858.CD008794.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1158\/1078-0432.CCR-06-1245","article-title":"Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients","volume":"12","author":"Ansell","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0192|cit192","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.thj.6200133","article-title":"Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment","volume":"2","author":"Bienvenu","year":"2001","journal-title":"The Hematology Journal : the official journal of the European Hematology Association \/ EHA"},{"issue":"17","key":"10.1002\/14651858.CD008794.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.anes.0000267518.20363.0d","article-title":"A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy","volume":"107","author":"Cohen","year":"2007","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ALN.0b013e3181a05aa0","article-title":"Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica","volume":"110","author":"Cohen","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/ard.2005.049650","article-title":"Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison","volume":"65","author":"Combe","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"30","key":"10.1002\/14651858.CD008794.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"Vos","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/rccm.200601-072OC","article-title":"The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma","volume":"174","author":"Erin","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0201|cit201","first-page":"128","article-title":"Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?","volume":"5","author":"Feist","year":"2009","journal-title":"Nature Clinical Practice Rheumatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0202|cit202","first-page":"34","article-title":"ATTAIN study: Efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to anti-TNF-alpha. [Spanish]","volume":"1","author":"Fernandez-Lopez","year":"2006","journal-title":"Reumatologia Clinica Suplementos"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Annals of Internal Medicine:"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/09546630600967166","article-title":"Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study","volume":"17","author":"Gottlieb","year":"2006","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","article-title":"Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group","volume":"49","author":"Kimby","year":"2008","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","article-title":"Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","article-title":"Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation","volume":"47","author":"Li","year":"2008","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0215|cit215","first-page":"854","article-title":"Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience","volume":"33","author":"Moreland","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","article-title":"Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study","volume":"65","author":"Nikas","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","article-title":"Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma","volume":"97","author":"Ogura","year":"2006","journal-title":"Cancer Science"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/17460816.3.5.429","article-title":"The OPTION trial: Inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis http:\/\/dx.doi.org\/10.2217\/17460816.3.5.429","volume":"3","author":"Ramos-Remus","year":"2008","journal-title":"Future Rheumatology"},{"issue":"19","key":"10.1002\/14651858.CD008794.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cncr.24518","article-title":"Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)","volume":"115","author":"Ribrag","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","article-title":"Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study","volume":"18","author":"Schroder","year":"2006","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0223|cit223","first-page":"46","article-title":"Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis","volume":"25 Suppl","author":"Sibilia","year":"2007","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0225|cit225","first-page":"649","article-title":"Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis","volume":"31","author":"Tesser","year":"2004","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0226|cit226","first-page":"25","article-title":"The AIM study: Efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to methotrexate. [Spanish]","volume":"1","author":"Tornero Molina","year":"2006","journal-title":"Reumatologia Clinica Suplementos"},{"issue":"9504","key":"10.1002\/14651858.CD008794.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"Heijde","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD008794.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2007.082529","article-title":"Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis","volume":"67","author":"Heijde","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2005.05827.x","article-title":"Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device","volume":"132","author":"Heeckeren","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/ard.2005.043299","article-title":"Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study","volume":"65","author":"Riel","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0232|cit232","first-page":"933","article-title":"Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. [Chinese]","volume":"16","author":"Xu","year":"2008","journal-title":"Journal of Experimental Hematology \/ Chinese Associationo of Pathhophysiology"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","article-title":"The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Dermato-Venereologica"},{"issue":"52","key":"10.1002\/14651858.CD008794.pub2-BIB0234|cit234","first-page":"1","article-title":"Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety","volume":"9","author":"Alonso-Ruiz","year":"2008","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0235|cit235","unstructured":"Becker LA Oxman AD Chapter 22: Overviews of Reviews In: Higgins JP, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0236|cit236","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","author":"Behm","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0237|cit237","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0238|cit238","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD008794.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0240|cit240","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006873.pub2","article-title":"Interventions for prevention of post-operative recurrence of Crohn's disease","author":"Doherty","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0241|cit241","unstructured":"Drug Information Online. Drugs.com FDA Approves First Rheumatoid Arthritis Indication for Rituxan http:\/\/www.drugs.com\/news\/fda-approves-first-rheumatoid-arthritis-indication-rituxan-1745.html"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0242|cit242","unstructured":"Food Drug Administration Etanercept Product Approval Information- Licensing Action 12\/2\/1998 http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080536.htm 1998"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0243|cit243","unstructured":"Food Drug Administration Medication Guide: Enbrel\u00ae (etanercept) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/103795s5359lbl.pdf"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0244|cit244","unstructured":"Food Drug Administration Remicade\u00ae (infliximab) for IV Injection http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm107722.pdf 1999"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0245|cit245","unstructured":"Food Drug Administration Kineret\u00ae (anakinra) Physician packet insert: Kineret\u00ae (anakinra) prescribing information http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080650.htm 2001"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0246|cit246","unstructured":"Food Drug Administration Humira\u00ae (adalimumab): Highlights of prescribing information http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s114lbl.pdf"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0247|cit247","unstructured":"Food Drug Administration Package Insert. HUMIRA\u00ae (adalimumab). Abbott Laboratories http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080610.htm 2002"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0248|cit248","unstructured":"Food Drug Administration Patient Information Sheet. Abatacept (marketed as Orencia\u00ae) http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/DrugandBiologicApprovalReports\/FastTrackApprovalReports\/ucm082380.htm 2005"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0249|cit249","unstructured":"Food Drug Administration Rituxan\u00ae (rituximab) http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm150747.htm"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0250|cit250","unstructured":"FDA: FDA Center for Drug Evaluation and Research SIMPONI\u00ae (Golimumab) Summary Review http:\/\/www.accessdata.fda.gov\/drugsatdfa_docs\/nda\/2009\/125289s000_SumR.pdf 2009"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0251|cit251","unstructured":"FDA SIMPONI\u00ae (Golimumab) Physician Packet Insert: Highlights of Prescribing Information http:\/\/www.accessdata.fda.gov\/drugsatdfa_docs\/label\/2009\/125289s000lbl.pdf 2009"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0252|cit252","unstructured":"Food Drug Administration Cimzia\u00ae (Certolizumab): Highlights of prescribing information http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125160s092lbl.pdf 2009"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0253|cit253","unstructured":"Food Drug Administration Drug details: Orencia\u00ae http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125118s0086lbl.pdf 2009"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0254|cit254","unstructured":"Food Drug Administration Remicade\u00ae (infliximab) for IV Injection http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103772s5234lbl.pdf 2009"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0255|cit255","unstructured":"FDA: Food Drug Administration Medication Guide. Actermra (Tocilizumab) http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM197463.pdf 2010"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0256|cit256","unstructured":"Food and Drug Administration. Department of Health and Human Services: Safety MedWatch: The FDA Safety information and adverse event reporting program: Reporting serious problems to FDA: What is a serious advent event? http:\/\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm."},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0257|cit257","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007940","article-title":"TNF-alpha inhibitors for psoriatic arthritis","author":"Golicki","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"18","key":"10.1002\/14651858.CD008794.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis. Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0260|cit260","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0b013e328329f84f","article-title":"Recent concepts in the inhibition of radiographic progression with biologics","volume":"21","author":"Keystone","year":"2009","journal-title":"Current Opinion in Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","article-title":"Epidemiology and burden of illness of rheumatoid arthritis","volume":"22 Suppl 1","author":"Kvien","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1002\/14651858.CD008794.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009740500327727","article-title":"Quality of life in rheumatoid arthritis","volume":"34","author":"Kvien","year":"2005","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00296-007-0475-6","article-title":"Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis","volume":"28","author":"Lee","year":"2008 April","journal-title":"Rheumatology International"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22 Suppl 1","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0266|cit266","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007277","article-title":"Abatacept for rheumatoid arthritis","author":"Maxwell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"10.1002\/14651858.CD008794.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2165\/0003495-200868170-00004","article-title":"Disease-modifying agents for multiple sclerosis: recent advances and future prospects","volume":"68","author":"Menge","year":"2008","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0268|cit268","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005121","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008794.pub2-BIB0269|cit269","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005113.pub2","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0270|cit270","doi-asserted-by":"publisher","DOI":"10.1002\/9780470434567.scard","volume-title":"Wiley Series in Computational Statistics, in Bayesian Modeling Using WinBUGS","author":"Ntzoufras","year":"2008"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/03009740510018633","article-title":"Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register","volume":"34","author":"Odegard","year":"2005","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008794.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0197-2456(97)00051-2","article-title":"Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis","volume":"18","author":"Pogue","year":"1997 Dec","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1529-8019.2008.01216.x","article-title":"New biologics for psoriasis and psoriatic arthritis","volume":"22","author":"Rozenblit","year":"2009","journal-title":"Dermatologic Therapy"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0275|cit275","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007649.pub2","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0276|cit276","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003805.pub2","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0277|cit277","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008) The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch11"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0278|cit278","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008) The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch12"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0280|cit280","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007848.pub2","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008794.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"Canadian Medical Association Journal"},{"issue":"7","key":"10.1002\/14651858.CD008794.pub2-BIB0282|cit282","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008331","article-title":"Tocilizumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0283|cit283","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008341","article-title":"Golimumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008794.pub2-BIB0284|cit284","unstructured":"Spiegelhalter D Thomas A Best N Lunn D WinBUGS user manual. Version 1.4 [Cambridge, UK]: BUGS Project; http:\/\/www.mrc-bsu.cam.ac.uk\/bugs\/winbugs\/manual14.pdf 2003 Jan"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0285|cit285","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"American Journal of Managed Care"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs."},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0287|cit287","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006552.pub2","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","author":"Vidal","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008794.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010 April","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD008794.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/BOR.0b013e3280126b66","article-title":"Work disability in rheumatic diseases","volume":"19","author":"Yelin","year":"2007","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008794.pub2-BIB0290|cit290","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Zochling","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008794.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T06:09:43Z","timestamp":1740895783000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008794.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":290,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008794.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10207956.10999054","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]}}}